JP2018503685A - 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物 - Google Patents

線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物 Download PDF

Info

Publication number
JP2018503685A
JP2018503685A JP2017556784A JP2017556784A JP2018503685A JP 2018503685 A JP2018503685 A JP 2018503685A JP 2017556784 A JP2017556784 A JP 2017556784A JP 2017556784 A JP2017556784 A JP 2017556784A JP 2018503685 A JP2018503685 A JP 2018503685A
Authority
JP
Japan
Prior art keywords
net
pad4
mice
fibrosis
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503685A5 (enExample
Inventor
デニサ ディー． ワグナー
デニサ ディー． ワグナー
シュウ リン ウォン
シュウ リン ウォン
Original Assignee
ザ・チルドレンズ・メディカル・センター・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・チルドレンズ・メディカル・センター・コーポレーション filed Critical ザ・チルドレンズ・メディカル・センター・コーポレーション
Publication of JP2018503685A publication Critical patent/JP2018503685A/ja
Publication of JP2018503685A5 publication Critical patent/JP2018503685A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017556784A 2015-01-20 2016-01-19 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物 Pending JP2018503685A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105342P 2015-01-20 2015-01-20
US62/105,342 2015-01-20
PCT/US2016/013847 WO2016118476A1 (en) 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing

Publications (2)

Publication Number Publication Date
JP2018503685A true JP2018503685A (ja) 2018-02-08
JP2018503685A5 JP2018503685A5 (enExample) 2019-02-21

Family

ID=56417634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556784A Pending JP2018503685A (ja) 2015-01-20 2016-01-19 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物

Country Status (5)

Country Link
US (3) US11400139B2 (enExample)
EP (2) EP3247386A4 (enExample)
JP (1) JP2018503685A (enExample)
CA (1) CA2974369A1 (enExample)
WO (1) WO2016118476A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550268A (ja) * 2019-09-06 2022-12-01 コンセホ、ナシオナル、デ、インベスティガシオネス、シエンティフィカス、イェ、テクニカス 局所創傷処置用の医薬組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351263A1 (en) * 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
IL317968A (en) 2017-08-18 2025-02-01 Neutrolis Inc Engineered deoxyribonuclease enzymes and their use in medicine
EP3761971A4 (en) * 2018-03-09 2021-11-10 The University of Memphis Research Foundation FLAMMATION INHIBITION COMPOSITIONS AND METHODS
EP3813555A4 (en) * 2018-06-29 2022-03-30 Tets, Viktor, Veniaminovich COMPOSITIONS FOR MODULATION OF INTESTINAL FLORA
GB202012326D0 (en) * 2020-08-07 2020-09-23 Citryll B V Diagnostic
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199329A1 (en) * 2011-05-27 2014-07-17 Children's Medical Center Corporation Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
WO2014168253A1 (ja) * 2013-04-09 2014-10-16 国立大学法人東京大学 白血球の細胞外トラップ形成の阻害剤

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US6919320B1 (en) * 1987-10-28 2005-07-19 Wellstat Therapeutics Corporation Pharmaceutical compositions containing deoxyribonucleosides for wound healing
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
DE68928934T2 (de) 1988-12-23 1999-08-05 Genentech, Inc., South San Francisco, Calif. Verfahren zur herstellung von menschlicher dnase
DE3903672C1 (enExample) 1989-02-08 1990-02-01 Lohmann Gmbh & Co Kg
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US5539878A (en) 1995-06-16 1996-07-23 Elonex Technologies, Inc. Parallel testing of CPU cache and instruction units
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
EP1156812A4 (en) 1999-02-23 2004-09-29 Isis Pharmaceuticals Inc MULTIPARTICULAR FORMULATION
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
CA2555199A1 (en) 2004-02-04 2005-08-18 Yokohama City University Peptidylarginine deiminase 4 inhibitor
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007056389A2 (en) 2005-11-07 2007-05-18 University Of South Carolina Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases
WO2009121183A1 (en) 2008-04-03 2009-10-08 Kane Biotech Inc. Dispersinbtm, 5-fluorouracil, deoxyribonuclease i and proteinase k-based antibiofilm compositions and uses thereof
KR20110063731A (ko) 2008-06-16 2011-06-14 치라릭스 비.브이. 펩티딜아르기닌 디이미나아제(ｐａｄ) 억제제
EP2775304A1 (en) * 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
GB201309180D0 (en) 2013-05-21 2013-07-03 Ucl Business Plc Compounds and Their Uses
WO2014206856A1 (en) * 2013-06-24 2014-12-31 Dentsply Ih Ab Medical device comprising collagen-vi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199329A1 (en) * 2011-05-27 2014-07-17 Children's Medical Center Corporation Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
WO2014168253A1 (ja) * 2013-04-09 2014-10-16 国立大学法人東京大学 白血球の細胞外トラップ形成の阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURRENT OPINION IN HEMATOLOGY, vol. 20, JPN6019045352, 2013, pages 3 - 9, ISSN: 0004300046 *
JOURNAL OF PATHOLOGY, vol. 233, JPN6019045349, 2014, pages 294 - 307, ISSN: 0004300045 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550268A (ja) * 2019-09-06 2022-12-01 コンセホ、ナシオナル、デ、インベスティガシオネス、シエンティフィカス、イェ、テクニカス 局所創傷処置用の医薬組成物
JP7657412B2 (ja) 2019-09-06 2025-04-07 コンセホ、ナシオナル、デ、インベスティガシオネス、シエンティフィカス、イェ、テクニカス 局所創傷処置用の医薬組成物

Also Published As

Publication number Publication date
EP3797789B1 (en) 2024-08-21
US20180271953A1 (en) 2018-09-27
US20230190886A1 (en) 2023-06-22
EP3247386A1 (en) 2017-11-29
CA2974369A1 (en) 2016-07-28
US11400139B2 (en) 2022-08-02
EP3247386A4 (en) 2018-10-03
EP3797789A1 (en) 2021-03-31
WO2016118476A1 (en) 2016-07-28
US20250242000A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
US20250242000A1 (en) Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
US20250262284A1 (en) Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
RU2636820C2 (ru) Способы и применения ингибиторов пропротеиновой конвертазы субтилизин кексин типа 9(pcsk9)
US9533002B2 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β
US20160333343A1 (en) Method of Treatment of Vascular Complications
WO2014180229A1 (zh) 仿生重组高密度脂蛋白在制备预防和治疗阿尔茨海默病药物中的应用
Han et al. p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cells
Hagiwara et al. An antisense oligonucleotide to HSP47 inhibits paraquat-induced pulmonary fibrosis in rats
KR20230155405A (ko) SARS-CoV-2-유도성 패혈증의 진단 또는 예후 예측용 바이오마커
US8748493B2 (en) Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
US20120142609A1 (en) Non human animal models for increased retinal vascular permeability
WO2024064879A2 (en) Interferon lambda (ifnl) inhibition in intestinal epithelial cells for treating inflammation
US20230340149A1 (en) Methods of treatment of inflammatory bowel diseases
WO2024097571A1 (en) Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
Mohammad Novel therapeutic targets for organ injury and dysfunction in systemic inflammation
Jiao et al. Alogliptin Reduces Oxidative Stress in Cardiomyocytes and Ameliorates Diabetic Cardiomyopathy via the AURKB/NLGN2 Signaling
Jawale et al. Metabolic ‘De-Programming’of Neutrophils Protects Against Fatal Bloodstream Fungal Infections in Kidney Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200706